E
E. David Crawford
Researcher at University of Colorado Hospital
Publications - 6
Citations - 4096
E. David Crawford is an academic researcher from University of Colorado Hospital. The author has contributed to research in topics: Prostate cancer screening & Cancer screening. The author has an hindex of 6, co-authored 6 publications receiving 3887 citations. Previous affiliations of E. David Crawford include Anschutz Medical Campus & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole,E. David Crawford,Robert L. Grubb,Saundra S. Buys,David Chia,Timothy R. Church,Mona N. Fouad,Edward P. Gelmann,Paul A. Kvale,Douglas J. Reding,Joel L. Weissfeld,Lance A. Yokochi,Jonathan D. Clapp,Joshua M. Rathmell,Thomas L. Riley,Richard B. Hayes,Barnett S. Kramer,Anthony B. Miller,Paul F. Pinsky,Philip C. Prorok,John K. Gohagan,Christine D. Berg +21 more
TL;DR: After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
Journal ArticleDOI
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
Gerald L. Andriole,E. David Crawford,Robert L. Grubb,Saundra S. Buys,David Chia,Timothy R. Church,Mona N. Fouad,Claudine Isaacs,Paul A. Kvale,Douglas J. Reding,Joel L. Weissfeld,Lance A. Yokochi,Barbara O'Brien,Lawrence R. Ragard,Jonathan D. Clapp,Joshua M. Rathmell,Thomas L. Riley,Ann W. Hsing,Grant Izmirlian,Paul F. Pinsky,Barnett S. Kramer,Barnett S. Kramer,Anthony B. Miller,John K. Gohagan,Philip C. Prorok +24 more
TL;DR: There was no evidence of a mortality benefit for organized annual screening in the PLCO trial compared with opportunistic screening, which forms part of usual care, and there was no apparent interaction with age, baseline comorbidity, or pretrial PSA testing.
Journal ArticleDOI
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
Robert L. Grubb,Paul F. Pinsky,Robert T. Greenlee,Grant Izmirlian,Anthony B. Miller,Thomas Hickey,Thomas L. Riley,Jerome Mabie,David L. Levin,David Chia,Barnett S. Kramer,Douglas J. Reding,Timothy R. Church,Lance A. Yokochi,Paul A. Kvale,Joel L. Weissfeld,Donald A. Urban,Saundra S. Buys,Edward P. Gelmann,Lawrence R. Ragard,E. David Crawford,Philip C. Prorok,John K. Gohagan,Christine D. Berg,Gerald L. Andriole +24 more
TL;DR: The results of the first four rounds of prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial indicate that annual screening with prostate‐specific antigen (PSA) and a digital rectal examination (DRE) reduces prostate cancer‐specific mortality.
Journal ArticleDOI
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.
Paul F. Pinsky,Eric A. Miller,Philip C. Prorok,Robert L. Grubb,E. David Crawford,Gerald L. Andriole +5 more
TL;DR: To examine prostate cancer incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, patients were randomly assigned to receive either a PLCO or a dummy pill.
Journal ArticleDOI
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.
Paul F. Pinsky,Barnett S. Kramer,E. David Crawford,Robert L. Grubb,Donald A. Urban,Gerald L. Andriole,David Chia,David L. Levin,John K. Gohagan +8 more
TL;DR: Prostate volume and age are independently associated with increased PSA levels in a population of men undergoing prostate cancer screening.